The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience

BACKGROUND: Genomic tests are increasingly being used by clinicians when considering adjuvant chemotherapy for patients with oestrogen receptor-positive (ER+), human epidermal growth factor 2-negative (HER2−) breast cancer. The Oncotype DX breast recurrence score assay was the first test available i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Crolley, Valerie E., Marashi, Husam, Rawther, Shabbir, Sirohi, Bhawna, Parton, Marina, Graham, Janine, Vinayan, Anup, Sutherland, Stephanie, Rigg, Anne, Wadhawan, Anshu, Harper-Wynne, Catherine, Spurrell, Emma, Bond, Hannah, Raja, Fharat, King, Judy
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2020
Assuntos:
Epidemiology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7103011/
https://ncbi.nlm.nih.gov/pubmed/32170635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05578-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados